×
About 357 results

ALLMedicine™ Ca 15-3 Center

Research & Reviews  177 results

Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival...
https://doi.org/10.2217/bmm-2020-0165
Biomarkers in Medicine; Moll SA, Wiertz IA et. al.

Sep 17th, 2020 - Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year foll...

How Useful Are Tumor Markers in Detecting Metastases with FDG-PET/CT during Breast Canc...
https://doi.org/10.1159/000507707
Oncology Corso G, Gilardi L et. al.

Jun 9th, 2020 - To assess the clinical usefulness of serum tumor markers for early detection of distant breast cancer recurrence using FDG-PET/CT. We retrospectively analyzed 561 consecutive patients who underwent surgery for invasive primary breast cancer and ha...

Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer P...
https://doi.org/10.21873/anticanres.14303
Anticancer Research; Dąbrowska E, Przylipiak A et. al.

Jun 2nd, 2020 - Chemokines are cytokines involved not only in inflammatory but also in inappropriate response of the immune system in breast cancer (BC) progression. We examined the diagnostic usefulness of CXCL12, CXCR4 and CA 15-3 in BC patients, based on ROC c...

CA 15-3 
https://emedicine.medscape.com/article/2087491-overview

Jan 12th, 2020 - Reference Range Cancer antigen 15-3 (CA 15-3) is used to monitor response to breast cancer treatment and disease recurrence. The reference range of serum CA 15-3 is less than 30 U/mL. The upper limit of the range varies depending on the laboratory...

CA 15-3 
https://emedicine.medscape.com/article/2087491-print

Jan 12th, 2020 - Cancer antigen 15-3 (CA 15-3) is used to monitor response to breast cancer treatment and disease recurrence. The reference range of serum CA 15-3 is less than 30 U/mL. The upper limit of the range varies depending on the laboratory and kit used fo...

see more →

Clinicaltrials.gov  179 results

Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival...
https://doi.org/10.2217/bmm-2020-0165
Biomarkers in Medicine; Moll SA, Wiertz IA et. al.

Sep 17th, 2020 - Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year foll...

How Useful Are Tumor Markers in Detecting Metastases with FDG-PET/CT during Breast Canc...
https://doi.org/10.1159/000507707
Oncology Corso G, Gilardi L et. al.

Jun 9th, 2020 - To assess the clinical usefulness of serum tumor markers for early detection of distant breast cancer recurrence using FDG-PET/CT. We retrospectively analyzed 561 consecutive patients who underwent surgery for invasive primary breast cancer and ha...

Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer P...
https://doi.org/10.21873/anticanres.14303
Anticancer Research; Dąbrowska E, Przylipiak A et. al.

Jun 2nd, 2020 - Chemokines are cytokines involved not only in inflammatory but also in inappropriate response of the immune system in breast cancer (BC) progression. We examined the diagnostic usefulness of CXCL12, CXCR4 and CA 15-3 in BC patients, based on ROC c...

CA 15-3 
https://emedicine.medscape.com/article/2087491-overview

Jan 12th, 2020 - Reference Range Cancer antigen 15-3 (CA 15-3) is used to monitor response to breast cancer treatment and disease recurrence. The reference range of serum CA 15-3 is less than 30 U/mL. The upper limit of the range varies depending on the laboratory...

CA 15-3 
https://emedicine.medscape.com/article/2087491-print

Jan 12th, 2020 - Cancer antigen 15-3 (CA 15-3) is used to monitor response to breast cancer treatment and disease recurrence. The reference range of serum CA 15-3 is less than 30 U/mL. The upper limit of the range varies depending on the laboratory and kit used fo...

see more →

News  1 results

Tumor DNA Marks Changes in Metastatic BRCA
https://www.medpagetoday.com/hematologyoncology/breastcancer/37892

Mar 14th, 2013 - Action Points Note that this proof-of-concept study demonstrated that circulating tumor DNA was detectable in 19 out of 20 women with metastatic breast cancer. Higher quartiles of circulating tumor DNA were strongly associated with worse overall m...

see more →